Prolacta Bioscience Inc.
http://prolacta.asia/home
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Prolacta Bioscience Inc.
Prolacta Formula Fortifier Starts Trial For Newborns With Rare Heart Condition
Prolacta Bioscience developed human milk-based formula fortifier for full-term infants born with conditions that make them vulnerable to nutrition deficiencies. Pending results from research at 12 US hospitals, the product would roll out commercially in 2018.
Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick
Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.
Industry News Roundup
Disclaimer alert symbol needed in ads; Prestige keeps Dramamine brand; DSM invests in omega-3s; Citizen petition to ban carrageenan withdrawn; NDAC to consider health care antiseptics; and Prolact CR cream supplement helps premature infants.
Industry News Roundup
Disclaimer alert symbol needed in ads; Prestige keeps Dramamine brand; DSM invests in omega-3s; Citizen petition to ban carrageenan withdrawn; NDAC to consider health care antiseptics; and Prolact CR cream supplement helps premature infants.
Company Information
- Industry
-
Pharmaceuticals
- Nutraceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice